Skip to main content

Canaccord Genuity Remains a Buy on Regeneron (REGN)

Tipranks - Tipranks - Tue Feb 24, 7:48AM CST

Canaccord Genuity analyst John Newman maintained a Buy rating on Regeneron today and set a price target of $1,057.00.

Claim 50% Off TipRanks Premium

Newman covers the Healthcare sector, focusing on stocks such as Arcellx Inc, Regeneron, and Compass Therapeutics. According to TipRanks, Newman has an average return of -0.5% and a 39.39% success rate on recommended stocks.

In addition to Canaccord Genuity, Regeneron also received a Buy from Citi’s Geoff Meacham in a report issued on February 18. However, on February 10, RBC Capital maintained a Hold rating on Regeneron (NASDAQ: REGN).

See today’s best-performing stocks on TipRanks >>

Based on Regeneron’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.88 billion and a net profit of $844.6 million. In comparison, last year the company earned a revenue of $3.79 billion and had a net profit of $917.7 million

Read More on REGN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).